Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional 
Investor Conference 
Company Presentation Will Be Webcast Live on Monday, March 3rd at
12:05 PM EST 
WELLESLEY, MA -- (Marketwired) -- 02/26/14 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company
and developer of the AC5 Surgical Hemostatic Device(TM), a novel
product aimed at controlling bleeding and fluid loss in order to
provide faster and safer surgical and interventional care, is pleased
to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to
present a corporate overview at The Wall Street Analyst Forum
Conference in Manhattan at The University Club of NYC on Monday,
March 3rd at 12:05 PM EST. 
The Arch Therapeutics presentation will be provided via a live audio
and high-definition video webcast and can be accessed at either of
the following links: or The presentation will be available
on the Arch website following the event at  
Arch Therapeutics recommends registering at least 10 minutes prior to
the start of the presentation to ensure timely access. You will
require a Microsoft Silverlight viewer (a free download from the
presentation link) to participate. 
About The Wall Street Analyst Forum Conferences 
Our March 2014 investor conference is our 24th Annual Investor
Conference. We have been a leading sponsor of institutional investor
conferences in New York City, Boston and London since 1989. Over 2200
corporations, from General Electric, Pfizer, Mattel to Nokia, have
presented. Institutional investors from 2000 money management firms
have attended. In 1998 we received extensive coverage in the
financial press for conducting the first live webcast of individual
corporate meetings from an investor conference. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board,
 Terrence W. Norchi, MD
 Arch Therapeutics,
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.